PMID- 26461116
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20181113
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Print)
IS  - 0142-9612 (Linking)
VI  - 74
DP  - 2016 Jan
TI  - Plasma membrane vesicles decorated with glycolipid-anchored antigens and 
      adjuvants via protein transfer as an antigen delivery platform for inhibition of 
      tumor growth.
PG  - 231-44
LID - S0142-9612(15)00782-6 [pii]
LID - 10.1016/j.biomaterials.2015.09.031 [doi]
AB  - Antigen delivered within particulate materials leads to enhanced antigen-specific 
      immunity compared to soluble administration of antigen. However, current delivery 
      approaches for antigen encapsulated in synthetic particulate materials are 
      limited by the complexity of particle production that affects stability and 
      immunogenicity of the antigen. Herein, we describe a protein delivery system that 
      utilizes plasma membrane vesicles (PMVs) derived from biological materials such 
      as cultured cells or isolated tissues and a simple protein transfer technology. 
      We show that these particulate PMVs can be easily modified within 4 h by a 
      protein transfer process to stably incorporate a glycosylphosphatidylinositol 
      (GPI)-anchored form of the breast cancer antigen HER-2 onto the PMV surface. 
      Immunization of mice with GPI-HER-2-modified-PMVs induced strong HER-2-specific 
      antibody responses and protection from tumor challenge in two different breast 
      cancer models. Further incorporation of the immunostimulatory molecules IL-12 and 
      B7-1 onto the PMVs by protein transfer enhanced tumor protection and induced 
      beneficial Th1 and Th2-type HER-2-specific immune responses. Since protein 
      antigens can be easily converted to GPI-anchored forms, these results demonstrate 
      that isolated plasma membrane vesicles can be modified with desired antigens 
      along with immunostimulatory molecules by protein transfer and used as a vaccine 
      delivery vehicle to elicit potent antigen-specific immunity.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Patel, Jaina M
AU  - Patel JM
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - Vartabedian, Vincent F
AU  - Vartabedian VF
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - Bozeman, Erica N
AU  - Bozeman EN
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, 
      USA.
FAU - Caoyonan, Brianne E
AU  - Caoyonan BE
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - Srivatsan, Sanjay
AU  - Srivatsan S
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - Pack, Christopher D
AU  - Pack CD
AD  - Metaclipse Therapeutics Corporation, 3175 Presidential Drive, Atlanta, GA 30340, 
      USA.
FAU - Dey, Paulami
AU  - Dey P
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA.
FAU - D'Souza, Martin J
AU  - D'Souza MJ
AD  - Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, 
      Atlanta, GA 30341, USA.
FAU - Yang, Lily
AU  - Yang L
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, 
      USA.
FAU - Selvaraj, Periasamy
AU  - Selvaraj P
AD  - Department of Pathology and Laboratory Medicine, Emory University School of 
      Medicine, Atlanta, GA 30322, USA. Electronic address: pselvar@emory.edu.
LA  - eng
GR  - F31 CA165632/CA/NCI NIH HHS/United States
GR  - R01 CA138993/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150928
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens)
RN  - 0 (Glycolipids)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Animals
MH  - Antigens/*chemistry
MH  - CHO Cells
MH  - Cell Membrane/chemistry
MH  - Cricetinae
MH  - Cricetulus
MH  - Glycolipids/*chemistry
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Neoplasms/immunology/pathology/*therapy
PMC - PMC4661141
MID - NIHMS726473
OTO - NOTNLM
OT  - Breast cancer
OT  - Plasma membrane vesicle
OT  - Protein transfer
OT  - Tumor antigens
OT  - Vaccine
COIS- Conflict of Interest: Dr. Selvaraj is a co-founder & equity holder of Metaclipse 
      Therapeutics Corporation, which is a startup company formed to develop 
      therapeutic cancer vaccines for humans using the protein transfer technology 
      described here for which he is a co-inventor. Writing assistance was not utilized 
      in the production of the manuscript.
EDAT- 2015/10/16 06:00
MHDA- 2016/10/26 06:00
PMCR- 2017/01/01
CRDT- 2015/10/14 06:00
PHST- 2015/04/04 00:00 [received]
PHST- 2015/09/19 00:00 [revised]
PHST- 2015/09/23 00:00 [accepted]
PHST- 2015/10/14 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/10/26 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - S0142-9612(15)00782-6 [pii]
AID - 10.1016/j.biomaterials.2015.09.031 [doi]
PST - ppublish
SO  - Biomaterials. 2016 Jan;74:231-44. doi: 10.1016/j.biomaterials.2015.09.031. Epub 
      2015 Sep 28.